Current Atherosclerosis Reports

, Volume 13, Issue 3, pp 215–224 | Cite as

Genetics of Redox Systems and Their Relationship with Cardiovascular Disease

  • Dan Farbstein
  • Yitzchak Z. Soloveichik
  • Nina S. Levy
  • Andrew P. Levy


As atherosclerosis is still one of the major causes of death in Western populations, it is important to identify those individuals who are at increased risk for the disease so that aggressive treatment may be administered as early as possible. Following the understanding that oxidative stress has a pivotal role in the development and progression of atherosclerosis, many polymorphisms in genes that are related to redox systems were examined for their association with increased risk for cardiovascular disease (CVD). Although many polymorphisms were studied, only a handful showed consistent relevance to CVD in different trials. This article focuses on six of these polymorphisms, examining their effect on the risk for CVD as well as their effect on protein expression and function. Reports regarding pharmacogenetic implications of these polymorphisms, where such exist, are discussed as well.


Cardiovascular disease CVD Redox Genetics Oxidative stress Vitamins 



This work was supported by grants from the Israel-US Binational Science Foundation, the Juvenile Diabetes Foundation, and the National Institutes of Health (NIH RO1DK085226).


All of the authors have received grants to their institution from the National Institutes of Health and the Juvenile Diabetes Research Foundation.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104(4):503–16.PubMedCrossRefGoogle Scholar
  2. 2.
    Kondo T, Hirose M, Kageyama K. Roles of oxidative stress and redox regulation in atherosclerosis. J Atheroscler Thromb. 2009;16(5):532–8.PubMedGoogle Scholar
  3. 3.
    Farbstein D, Levy AP. The genetics of vascular complications in diabetes mellitus. Cardiol Clin. 2010;28(3):477–96.PubMedCrossRefGoogle Scholar
  4. 4.
    Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hall AV, Shi XM, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem. 1993;268(23):17478–88.PubMedGoogle Scholar
  5. 5.
    Dudzinski DM, Michel T. Life history of eNOS: partners and pathways. Cardiovasc Res. 2007;75(2):247–60.PubMedCrossRefGoogle Scholar
  6. 6.
    Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res. 1999;43(3):521–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Napoli C, Ignarro LJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch Pharm Res. 2009;32(8):1103–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Napoli C, Ignarro LJ. Polymorphisms in endothelial nitric oxide synthase and carotid artery atherosclerosis. J Clin Pathol. 2007;60(4):341–4.PubMedCrossRefGoogle Scholar
  9. 9.
    McDonald DM, Alp NJ, Channon KM. Functional comparison of the endothelial nitric oxide synthase Glu298Asp polymorphic variants in human endothelial cells. Pharmacogenetics. 2004;14(12):831–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Naber CK, Baumgart D, Altmann C, Siffert W, Erbel R, Heusch G. eNOS 894 T allele and coronary blood flow at rest and during adenosine-induced hyperemia. Am J Physiol. 2001;281(5):H1908–1912.Google Scholar
  11. 11.
    Rossi GP, Taddei S, Virdis A, Cavallin M, Ghiadoni L, Favilla S, et al. The T-786 C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol. 2003;41(6):938–45.PubMedCrossRefGoogle Scholar
  12. 12.
    Gulec S, Karabulut H, Ozdemir AO, Ozdol C, Turhan S, Altin T, et al. Glu298Asp polymorphism of the eNOS gene is associated with coronary collateral development. Atherosclerosis. 2008;198(2):354–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Miyamoto Y, Saito Y, Nakayama M, Shimasaki Y, Yoshimura T, Yoshimura M, et al. Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786 T– > C mutation associated with coronary spastic angina. Hum Mol Genet. 2000;9(18):2629–37.PubMedCrossRefGoogle Scholar
  14. 14.
    Wang XL, Sim AS, Wang MX, Murrell GA, Trudinger B, Wang J. Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. FEBS Lett. 2000;471(1):45–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Jeerooburkhan N, Jones LC, Bujac S, Cooper JA, Miller GJ, Vallance P, et al. Genetic and environmental determinants of plasma nitrogen oxides and risk of ischemic heart disease. Hypertension. 2001;38(5):1054–61.PubMedCrossRefGoogle Scholar
  16. 16.
    Li J, Wu X, Li X, Feng G, He L, Shi Y. The endothelial nitric oxide synthase gene is associated with coronary artery disease: a meta-analysis. Cardiology. 2010;116(4):271–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Casas JP, Cavalleri GL, Bautista LE, Smeeth L, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol. 2006;164(10):921–35.PubMedCrossRefGoogle Scholar
  18. 18.
    Comhair SA, Erzurum SC. The regulation and role of extracellular glutathione peroxidase. Antioxid Redox Signal. 2005;7(1–2):72–9.PubMedCrossRefGoogle Scholar
  19. 19.
    • Margis R, Dunand C, Teixeira FK, Margis-Pinheiro M: Glutathione peroxidase family - an evolutionary overview. FEBS J 2008, 275(15):3959–3970. This is an excellent review of the glutathione peroxidase family of proteins and their functions.Google Scholar
  20. 20.
    Voetsch B, Loscalzo J. Genetic determinants of arterial thrombosis. Arterioscler Thromb Vasc Biol. 2004;24(2):216–29.PubMedCrossRefGoogle Scholar
  21. 21.
    Voetsch B, Jin RC, Bierl C, Benke KS, Kenet G, Simioni P, et al. Promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene: a novel risk factor for arterial ischemic stroke among young adults and children. Stroke. 2007;38(1):41–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Kenet G, Freedman J, Shenkman B, Regina E, Brok-Simoni F, Holzman F, et al. Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. Arterioscler Thromb Vasc Biol. 1999;19(8):2017–23.PubMedGoogle Scholar
  23. 23.
    • Voetsch B, Jin RC, Bierl C, Deus-Silva L, Camargo EC, Annichino-Bizacchi JM, Handy DE, Loscalzo J: Role of promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene as a risk factor for cerebral venous thrombosis. Stroke 2008, 39(2):303–307. This article demonstrates the importance of glutathione peroxidase polymorphism in stroke risk.Google Scholar
  24. 24.
    Lei XG, Cheng WH, McClung JP. Metabolic regulation and function of glutathione peroxidase-1. Annu Rev Nutr. 2007;27:41–61.PubMedCrossRefGoogle Scholar
  25. 25.
    Hamanishi T, Furuta H, Kato H, Doi A, Tamai M, Shimomura H, et al. Functional variants in the glutathione peroxidase-1 (GPx-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in japanese type 2 diabetic patients. Diabetes. 2004;53(9):2455–60.PubMedCrossRefGoogle Scholar
  26. 26.
    Nemoto M, Nishimura R, Sasaki T, Hiki Y, Miyashita Y, Nishioka M, et al. Genetic association of glutathione peroxidase-1 with coronary artery calcification in type 2 diabetes: a case control study with multi-slice computed tomography. Cardiovasc Diabetol. 2007;6:23.PubMedCrossRefGoogle Scholar
  27. 27.
    Winter JP, Gong Y, Grant PJ, Wild CP. Glutathione peroxidase 1 genotype is associated with an increased risk of coronary artery disease. Coron Artery Dis. 2003;14(2):149–53.PubMedCrossRefGoogle Scholar
  28. 28.
    Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med. 2003;349(17):1605–13.PubMedCrossRefGoogle Scholar
  29. 29.
    Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem. 1990;1(5):228–37.PubMedCrossRefGoogle Scholar
  30. 30.
    Jakubowski H. The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. J Physiol Pharmacol. 2008;59 Suppl 9:155–67.PubMedGoogle Scholar
  31. 31.
    Obeid R, Herrmann W. Homocysteine and lipids: S-adenosyl methionine as a key intermediate. FEBS Lett. 2009;583(8):1215–25.PubMedCrossRefGoogle Scholar
  32. 32.
    Nygard O, Vollset SE, Refsum H, Brattstrom L, Ueland PM. Total homocysteine and cardiovascular disease. J Intern Med. 1999;246(5):425–54.PubMedCrossRefGoogle Scholar
  33. 33.
    Kerkeni M, Tnani M, Chuniaud L, Miled A, Maaroufi K, Trivin F. Comparative study on in vitro effects of homocysteine thiolactone and homocysteine on HUVEC cells: evidence for a stronger proapoptotic and proinflammative homocysteine thiolactone. Mol Cell Biochem. 2006;291(1–2):119–26.PubMedCrossRefGoogle Scholar
  34. 34.
    Chang PY, Lu SC, Lee CM, Chen YJ, Dugan TA, Huang WH, et al. Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast growth factor-2 involving G protein and DNA methylation. Circ Res. 2008;102(8):933–41.PubMedCrossRefGoogle Scholar
  35. 35.
    Tsai JC, Wang H, Perrella MA, Yoshizumi M, Sibinga NE, Tan LC, et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Investig. 1996;97(1):146–53.PubMedCrossRefGoogle Scholar
  36. 36.
    McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56(1):111–28.PubMedGoogle Scholar
  37. 37.
    Van Guelpen B, Hultdin J, Johansson I, Witthoft C, Weinehall L, Eliasson M, et al. Plasma folate and total homocysteine levels are associated with the risk of myocardial infarction, independently of each other and of renal function. J Intern Med. 2009;266(2):182–95.PubMedCrossRefGoogle Scholar
  38. 38.
    Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. Jama. 2008;299(17):2027–36.PubMedCrossRefGoogle Scholar
  39. 39.
    Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567–77.PubMedCrossRefGoogle Scholar
  40. 40.
    Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet. 2007;369(9576):1876–82.PubMedCrossRefGoogle Scholar
  41. 41.
    Lewis SJ, Ebrahim S, Davey Smith G: Meta-analysis of MTHFR 677 C- > T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ (Clinical research ed 2005, 331(7524):1053.Google Scholar
  42. 42.
    • Shih DM, Lusis AJ: The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Current opinion in lipidology 2009, 20(4):288–292. This is an excellent review of paraoxonase biology and its relationship to cardiovascular disease.Google Scholar
  43. 43.
    Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res. 2005;46(6):1239–47.PubMedCrossRefGoogle Scholar
  44. 44.
    Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21(4):473–80.PubMedGoogle Scholar
  45. 45.
    Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286(1–2):152–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Investig. 1995;96(6):2882–91.PubMedCrossRefGoogle Scholar
  47. 47.
    Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394(6690):284–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, et al. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem. 2000;275(23):17527–35.PubMedCrossRefGoogle Scholar
  49. 49.
    Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002;106(4):484–90.PubMedCrossRefGoogle Scholar
  50. 50.
    Deakin S, Leviev I, Brulhart-Meynet MC, James RW. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. Biochem J. 2003;372(Pt 2):643–9.PubMedCrossRefGoogle Scholar
  51. 51.
    Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet. 2004;363(9410):689–95.PubMedCrossRefGoogle Scholar
  52. 52.
    Najafi M, Gohari LH, Firoozrai M. Paraoxonase 1 gene promoter polymorphisms are associated with the extent of stenosis in coronary arteries. Thromb Res. 2009;123(3):503–10.PubMedCrossRefGoogle Scholar
  53. 53.
    Gaidukov L, Rosenblat M, Aviram M, Tawfik DS. The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J Lipid Res. 2006;47(11):2492–502.PubMedCrossRefGoogle Scholar
  54. 54.
    • Dahabreh IJ, Kitsios GD, Kent DM, Trikalinos TA: Paraoxonase 1 polymorphisms and ischemic stroke risk: A systematic review and meta-analysis. Genet Med 2010, 12(10):606–615. This article is a recent comprehensive meta-analysis of paraoxonase polymorphisms and their relationship.Google Scholar
  55. 55.
    Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscler Thromb Vasc Biol. 2003;23(8):1465–71.PubMedCrossRefGoogle Scholar
  56. 56.
    Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. Jama. 2008;299(11):1265–76.PubMedCrossRefGoogle Scholar
  57. 57.
    Miao L, St Clair DK. Regulation of superoxide dismutase genes: implications in disease. Free Radic Biol Med. 2009;47(4):344–56.PubMedCrossRefGoogle Scholar
  58. 58.
    Lebovitz RM, Zhang H, Vogel H, Cartwright Jr J, Dionne L, Lu N, et al. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci USA. 1996;93(18):9782–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Jones DA, Prior SL, Tang TS, Bain SC, Hurel SJ, Humphries SE, Stephens JW: Association between the rs4880 superoxide dismutase 2 (C > T) gene variant and coronary heart disease in diabetes mellitus. Diabetes Res Clin Pract 2010.Google Scholar
  60. 60.
    Mollsten A, Marklund SL, Wessman M, Svensson M, Forsblom C, Parkkonen M, et al. A functional polymorphism in the manganese superoxide dismutase gene and diabetic nephropathy. Diabetes. 2007;56(1):265–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Fujimoto H, Kobayashi H, Ogasawara K, Yamakado M, Ohno M. Association of the manganese superoxide dismutase polymorphism with vasospastic angina pectoris. J Cardiol. 2010;55(2):205–10.PubMedCrossRefGoogle Scholar
  62. 62.
    Fujimoto H, Taguchi J, Imai Y, Ayabe S, Hashimoto H, Kobayashi H, et al. Manganese superoxide dismutase polymorphism affects the oxidized low-density lipoprotein-induced apoptosis of macrophages and coronary artery disease. Eur Heart J. 2008;29(10):1267–74.PubMedCrossRefGoogle Scholar
  63. 63.
    Bowman BH, Kurosky A: Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Advances in human genetics 1982, 12:189–261, 453–184.Google Scholar
  64. 64.
    • Levy AP, Asleh R, Blum S, Levy NS, Miller-Lotan R, Kalet-Litman S, Anbinder Y, Lache O, Nakhoul FM, Asaf R et al: Haptoglobin: Basic and Clinical Aspects. Antioxidants & redox signaling 2009. This is an excellent summary of work showing basic mechanisms and clinical studies showing the importance of the haptoglobin polymorphism in predicting risk of CVD in diabetes.Google Scholar
  65. 65.
    Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42(10):1589–600.PubMedGoogle Scholar
  66. 66.
    Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G: Haptoglobin and risk of myocardial infarction, stroke, and congestive heart failure in 342,125 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Annals of medicine 2009:1–11.Google Scholar
  67. 67.
    • Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, Alshiek J, Bennett L, Kostenko M, Landau M et al: Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2–2 genotype: a prospective double-blinded clinical trial. Arteriosclerosis, thrombosis, and vascular biology 2008, 28(2):341–347. This prospective, placebo-controlled pharmacogenomic study showed that vitamin E provides significant cardiovascular protection to individuals with diabetes and the haptoglobin 2–2 genotype.Google Scholar
  68. 68.
    Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM, et al. Structure-function analysis of the antioxidant properties of haptoglobin. Blood. 2001;98(13):3693–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res. 2003;92(11):1193–200.PubMedCrossRefGoogle Scholar
  70. 70.
    Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res. 2005;96(4):435–41.PubMedCrossRefGoogle Scholar
  71. 71.
    Timmermann M, Hogger P. Oxidative stress and 8-iso-prostaglandin F(2alpha) induce ectodomain shedding of CD163 and release of tumor necrosis factor-alpha from human monocytes. Free Radic Biol Med. 2005;39(1):98–107.PubMedCrossRefGoogle Scholar
  72. 72.
    Boyle JJ, Harrington HA, Piper E, Elderfield K, Stark J, Landis RC, et al. Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype. Am J Pathol. 2009;174(3):1097–108.PubMedCrossRefGoogle Scholar
  73. 73.
    Asleh R, Blum S, Kalet-Litman S, Alshiek J, Miller-Lotan R, Asaf R, et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2–2 genotype. Diabetes. 2008;57(10):2794–800.PubMedCrossRefGoogle Scholar
  74. 74.
    Farbstein D, Levy AP. Pharmacogenomics and the prevention of vascular complications in diabetes mellitus. Therapy. 2009;6(4):531–8.CrossRefGoogle Scholar
  75. 75.
    Pare G, Chasman DI, Parker AN, Zee RR, Malarstig A, Seedorf U, et al. Novel associations of CPS1, MUT, NOX4, and DPEP1 with plasma homocysteine in a healthy population: a genome-wide evaluation of 13 974 participants in the Women’s Genome Health Study. Circ Cardiovasc Genet. 2009;2(2):142–50.PubMedCrossRefGoogle Scholar
  76. 76.
    O’Donnell CJ, Cupples LA, D’Agostino RB, Fox CS, Hoffmann U, Hwang SJ, Ingellson E, Liu C, Murabito JM, Polak JF et al: Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI’s Framingham Heart Study. BMC Med Genet 2007, 8 Suppl 1:S4.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Dan Farbstein
    • 1
  • Yitzchak Z. Soloveichik
    • 1
  • Nina S. Levy
    • 1
  • Andrew P. Levy
    • 1
  1. 1.The Ruth and Bruce Faculty of MedicineTechnion Israel Institute of TechnologyHaifaIsrael

Personalised recommendations